# Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19

> **NCT05122234** · PHASE3 · COMPLETED · sponsor: **Indonesia University** · enrollment: 40 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Injection of secretome - mesenchymal stem cell
- **OTHER:** Placebo
- **DRUG:** Standard treatment of Covid-19

## Key facts

- **NCT ID:** NCT05122234
- **Lead sponsor:** Indonesia University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-11-14
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05122234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05122234, "Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05122234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*